{
  "id": "7fbd8c77f7b72943",
  "title": "Pfizer boosts its obesity plans with $2bn GLP - 1 YaoPharma deal",
  "description": "20251210T144500Z",
  "content": "",
  "source": "europeanpharmaceuticalreview.com",
  "source_url": "https://www.europeanpharmaceuticalreview.com/news/268992/pfizer-boosts-its-obesity-plans-with-2bn-glp-1-yaopharma-deal/",
  "published_at": "20251210T144500Z",
  "fetched_at": "2025-12-11T00:23:03.006755+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "United Kingdom",
  "raw_data": {
    "url": "https://www.europeanpharmaceuticalreview.com/news/268992/pfizer-boosts-its-obesity-plans-with-2bn-glp-1-yaopharma-deal/",
    "url_mobile": "",
    "title": "Pfizer boosts its obesity plans with $2bn GLP - 1 YaoPharma deal",
    "seendate": "20251210T144500Z",
    "socialimage": "https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Pfizer-nitrosamine-FI.jpg",
    "domain": "europeanpharmaceuticalreview.com",
    "language": "English",
    "sourcecountry": "United Kingdom"
  }
}